Bioforce Nanosciences Holdings, Inc.

BFNH OTC SEC CIK 1310488
Follow Bioforce Nanosciences Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income $238.7K +294.4% vs same quarter last year
EPS, diluted $0.01
Operating cash flow −$27K +3.3% vs same quarter last year
Net income by quarter
−$122K
−$123.2K
−$935.5K
−$122.8K
−$115.9K
−$118.6K
−$102.4K
$238.7K
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$200M−$150M−$100M−$50M$0$50MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$1.3M
FY24-−$490.4K
FY23-−$472K
FY22-−$485.5K
FY21-−$502K
FY20-−$158.4M
FY19$17.8K−$46.5K
FY18$16.3K−$67.7K
FY17$4.5K−$31.3K
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−800%−600%−400%−200%0%200%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25---
FY24---
FY23---
FY22---
FY21---
FY20---
FY1924.5%−261.8%−261.8%
FY1828.6%−409.2%−415.3%
FY1727.9%−694.7%−694.7%
FY16---
Net margin vs the sectorMedian of Technology companies filing with the SEC
  • Bioforce Nanosciences
  • Technology median
−800%−600%−400%−200%0%200%FY17FY19FY21FY23FY25
Show the numbers
YearBioforce NanosciencesTechnology median
FY25-8.4%
FY24-8.9%
FY23-7.7%
FY22-5.9%
FY21-9.8%
FY20-4.5%
FY19−261.8%8.6%
FY18−415.3%6.3%
FY17−694.7%6.4%
FY16-5.3%

News

No stories filed under Bioforce Nanosciences yet - coverage appears here as the news feed clusters it.